Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

celebratelife Dec. 5 at 6:09 AM

$KPTI is going on involving options. Today it was about May 2026 2.50 and 5 puts. Any of you have an explanation? I posted earlier about some possibilities. One possibility is a bull put spread where they're selling higher strike puts and buying lower strikes as protection but I have no idea. It's more likely that this is a bullish move than a bearish move but I'm not an expert in this. It doesn't look like it's reverse conversion - we had some cockroaches who were involved in that stopped by FINRA in another stock: https://www.rezamusic.com/writings/law-ethics/reverse-conversions-scam

0 · Reply

celebratelife Dec. 4 at 10:37 PM

$KPTI Another letter on firing Paulson: Link to a shareholder letter to Karyopharm Board asking for firing of Richard Paulson is provided below. Here's an intro to the topic: With a track record of 99% drop in KPTI despite a life-saving, cancer curing drug, Richard Paulson has been a total disgrace and let down to Karyopharm shareholders. The letter that was sent to the Board (link below) has a simple, sensible thesis for why firing Paulson is an absolute must for Karyopharm to have a chance of success and turnaround. Paulson has been the worst, most irresponsible, most incompetent CEO I've ever come across in years of investing, and years of working with world-class organizations. It's a mystery why the Board (Barry E. Greene, Garen Bohlin, Chen Schor, Deepa R. Pakianathan, Christy J. Oliger, Dr. Zhen Su - and Mansoor Mirza while he was a long-term director) have not fired (rest of the letter here: https://www.rezamusic.com/writings/law-ethics/KPTI-Mismanagement#h.f27f6y22p6y3

0 · Reply

celebratelife Dec. 4 at 7:07 PM

$KPTI On KPTI option action 3 and 4 December 2025 Someone doubled their option to sell KPTI at 2.50/share in January by paying $14000 for being to sell 140,000 shares at 2.50. It doesn't seem to be opening of a short position (sell option to sell). If it is, the market makers bought it for 10 cents a share and it's bullish but on the face of it it's bearish. It could be bullish if the guy is so sure it won't go below 2.50 and he wanted to pocket another 14,000 yesterday. They also increased their $5 FEB puts and also today for a total of about 170,000 to sell at $5 in February. The Feb 5 is going between bid and ask price so it's hard to know what it is. Same with May $5 Open interest (rest of article on: https://www.rezamusic.com/writings/law-ethics/KPTI-Mismanagement#h.we4gusa9t146 )

0 · Reply

celebratelife Dec. 4 at 7:06 PM

$KPTI PAULSON BEING EXCITED MEANS DIDDLY SHIT FOR COMPANY VALUE BECAUSE HE'S A CURSE FOR KARYOPHARM AND THE BOARD IS RESPONSIBLE FOR THAT. Next time Paulson says "We're excited about the opportunity" I'll vomit. He's said that for 5 years as he's killed KPTI by 99% while shorts have made a killing, shareholders have lost their shorts, and insiders like Paulson have also made a killing - big salary and bonus (not tied to share performance) and lucrative perks. The fucking opportunity this lousy value-destroyer, irresponsible CEO is excited about has NEVER turned into value for shareholders, and it absolutely could have if he had applied financial discipline which he didn't because he's never had to in his past jobs working for rich pharmas, so he's clueless what real austerity measures mean, and he never wanted to sacrifice his perks and millions he's paid for doing jack shit that's ever translated to value, and running a 5-star vacation club... rest of article: https://www.rezamusic.com/writings/law-ethics/KPTI-Mismanagement

0 · Reply

celebratelife Dec. 3 at 1:45 AM

$KPTI Richard Paulson and the Board's apparent attitude towards shareholders...

0 · Reply

celebratelife Dec. 2 at 10:26 PM

$KPTI Letter from group of shareholders to the Board asking for firing of Richard Paulson. Solid reasoning: https://www.rezamusic.com/writings/law-ethics/KPTI-Mismanagement#h.wv4dpq2zyn5g

1 · Reply

celebratelife Dec. 2 at 10:14 PM

$KPTI Short interest up after getting bailed out bigtime recently. They're not afraid of these clowns. Miracle can happen. But can this self-serving, entitled, lazy, ineffective, value destroyed Paulson pull it off? He better. Paulson and the Board members are accountable and liable.

0 · Reply

celebratelife Dec. 2 at 8:12 PM

$KPTI Board of any normal company would have fired CEO Richard Paulson in no time. He’s been tolerated for almost 5 years, destroying the stock year after year, while splurging the hell out of our cash by giving away HUGE sums that we don’t have (and raised through diluting us and toxic financing) to likes of Dempsey, necessary travels, free daily catered lunches for everyone, vacation club types of culture, work fit for life blah blah, spoiled unproductive entitled culture (Lisa DiPaolo even hinted on YouTube effectively how spoiled and entitled they are). Paulson is the epidemy of that entitled, arrogant, ignorant position, which has cost us almost a BILLION DOLLARS in market cap while shorts have made a killing and absolutely LOVE this lousy CEO. The Board led by Barry Greene are accountable and liable for this value destruction due to their breach of their duties and ignoring their mandate.

0 · Reply

celebratelife Dec. 2 at 8:00 PM

$KPTI KPTI’s own 3 stooges: Richard Paulson, Mike Mano, Mike Mason. Value down ~a billion dollars on their watch, and they’ve been paid millions despite piss poor, horrific, irresponsible mismanagement. They + the Board are liable and accountable to us shareholders.

0 · Reply

celebratelife Dec. 1 at 12:56 AM

$KPTI SUCKERS OF OUR CAPITAL: RICHARD “PARTY” PAULSON, BARRY GREENE, MANSOOR MIRZA, GAREN BOHLIN, DEEPA PAKIANATHAN, CHEN SCHOR, MIKE MANO, CHRISTY OLIGER, ZHEN SU, LISA DIPAOLO, MIKE MASON

0 · Reply

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2025, 7:00 AM EST - 4 days ago

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 3, 2025, 1:26 PM EST - 4 weeks ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 7:00 AM EST - 4 weeks ago

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Oct 27, 2025, 7:00 AM EDT - 5 weeks ago

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 8, 2025, 1:31 PM EDT - 2 months ago

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct 8, 2025, 7:00 AM EDT - 2 months ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Sep 10, 2025, 7:00 AM EDT - 3 months ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Aug 11, 2025, 11:02 AM EDT - 4 months ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:30 AM EDT - 4 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 5, 2025, 7:00 AM EDT - 4 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Jun 3, 2025, 8:00 AM EDT - 6 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 7 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 7 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 13, 2025, 1:39 PM EDT - 7 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 7:15 AM EDT - 7 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 7 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 7 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 5, 2025, 12:00 AM EST - 9 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 10 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 11:05 AM EST - 10 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:30 AM EST - 10 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 10 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 10 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 11 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 9, 2024, 8:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 3, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:22 PM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

celebratelife Dec. 5 at 6:09 AM

0 · Reply

celebratelife Dec. 4 at 10:37 PM

0 · Reply

celebratelife Dec. 4 at 7:07 PM

0 · Reply

celebratelife Dec. 4 at 7:06 PM

0 · Reply

celebratelife Dec. 3 at 1:45 AM

$KPTI Richard Paulson and the Board's apparent attitude towards shareholders...

0 · Reply

celebratelife Dec. 2 at 10:26 PM

$KPTI Letter from group of shareholders to the Board asking for firing of Richard Paulson. Solid reasoning: https://www.rezamusic.com/writings/law-ethics/KPTI-Mismanagement#h.wv4dpq2zyn5g

1 · Reply

celebratelife Dec. 2 at 10:14 PM

0 · Reply

celebratelife Dec. 2 at 8:12 PM

0 · Reply

celebratelife Dec. 2 at 8:00 PM

0 · Reply

celebratelife Dec. 1 at 12:56 AM

$KPTI SUCKERS OF OUR CAPITAL: RICHARD “PARTY” PAULSON, BARRY GREENE, MANSOOR MIRZA, GAREN BOHLIN, DEEPA PAKIANATHAN, CHEN SCHOR, MIKE MANO, CHRISTY OLIGER, ZHEN SU, LISA DIPAOLO, MIKE MASON

0 · Reply

celebratelife Nov. 29 at 3:23 PM

$KPTI

0 · Reply

celebratelife Nov. 27 at 6:29 PM

$KPTI I deactivated the Twitter (X) account. I just got tired of X which I've never liked. So if you click on any old links and the posts are not there, it's because I deleted them before closing the account. They're all still available on my website: https://www.rezamusic.com/writings/law-ethics/KPTI-Mismanagement Meanwhile we're getting ducks in a row to hold these self-serving, unethical, incompetent value destroyers to account - legally. You reap what you sow. Here's a goodie for you:

1 · Reply

celebratelife Nov. 26 at 3:20 PM

$KPTI Paulson, Mano, Greene's extremely weak profile: https://x.com/karyowatch/status/1993698175522341174

0 · Reply

laaarsas Nov. 25 at 2:08 AM

$KPTI I tried to contact company with these questions, anyone knows the answers? 1. Why was TSS50 changed to Abs-TSS? 2. Exactly how till Abs-TSS be measured? Landmark measure att 24w? Or is entire period taken into account? 3. What was the MCID that the trial was designed after in terms of Abs-TSS? 4. What is the lowest Abs-TSS that can be measured with preserved statistical significance?

1 · Reply

celebratelife Nov. 24 at 11:46 PM

$KPTI IMPACT OF TODAY'S SEC FILINGS: https://x.com/karyowatch/status/1993103581730554038

0 · Reply

mich1282 Nov. 24 at 4:34 PM

$KPTI doesn’t want to play today?

1 · Reply

WallStreetBuyDip Nov. 24 at 1:44 AM

$KPTI on watch. will buy when H% is low like shown here

0 · Reply

celebratelife Nov. 23 at 11:49 PM

$KPTI 5 years of value destruction by Richard Paulson et al.: https://x.com/karyowatch/status/1992742077113983103

0 · Reply

celebratelife Nov. 23 at 11:37 PM

$KPTI Great science: https://x.com/karyowatch/status/1992739128157618508

0 · Reply

Night_Owl_Biotech Nov. 22 at 4:36 PM

There are 24 commercial-stage oncology focused bios with collective enterprise values that are less than 1% of the 14 most valuable Big Pharmas. Put simply, these 24 all have FDA approved cancer therapies yet are barely rounding errors compared to BP's valuation. The attachment graphs the perspective visually. Hence we simply cannot believe $IOVA & their TIL & $AUTL's T-cells are not obvious synergistic fits into 3 or 4 BP pipelines. On the $SNDX v $KURA debate, there are other menin inhibitors from Astra Zeneca & J&J in development. Hence both provide peer BP's a pathway to this high TAM opportunity. Consistent with our post from yesterday outlining what's happened to all 61 new comm'l-stage oncology focused bios since 1/1/13, shareholders lose in those that wait like $KPTI & PBYI. Everyone wins in M&A, especially healthcare costs in general via scale from consolidation.

6 · Reply

celebratelife Nov. 22 at 4:05 PM

$KPTI Reasons Richard Paulson's destroying hundreds of millions in value: https://x.com/karyowatch/status/1992262446170751224

0 · Reply

celebratelife Nov. 22 at 4:00 PM

$KPTI About CEO Richard Paulson: https://x.com/karyowatch/status/1992261646681854198

0 · Reply

Market Cap	93.10M
Revenue (ttm)	145.24M
Net Income (ttm)	-76.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.62%
Debt to Equity Ratio	-0.36

Volume	134,700
Avg Vol	192,230
Day's Range	N/A - N/A
Shares Out	17.05M
Stochastic %K	19%
Beta	0.23
Analysts	Strong Sell
Price Target	$14.67